DCTH Delcath stock news
On July 9, 2026, Delcath Systems Inc. (DCTH) announced that the first patient has been dosed in its global Phase 2 clinical trial evaluating the HEPZATO KIT for liver--dominant metastatic breast cancer. This randomized, controlled study compares the efficacy of HEPZATO plus standard of care against standard of care alone in HER2--negative patients who have failed prior therapies. The trial is expected to enroll approximately 90 patients across more than 20 sites in the U.S. and Europe, with hepatic progression--free survival as the primary endpoint. The company estimates that approximately 7,000 patients in the U.S. annually are candidates for this treatment, marking a significant clinical expansion for the HEPZATO platform beyond its initial uveal melanoma indication.